Absorb scaffold

DEVICE3 trials

Sponsors

Rudolf Berger, IHF GmbH - Institut für Herzinfarktforschung, European Cardiovascular Research Center

Conditions

Bioresorbable ScaffoldsCoronary Artery LesionCoronary Artery Stenosis

Unknown Phase

Performance of Bioabsorbable Vascular Scaffolds (Absorb) Compared to Xience Stents - an Optical Coherence Tomography Study

Rudolf BergerBioresorbable Scaffolds

Start: 2013-11-30Target: 60Updated: 2013-12-04

Observational Study to Evaluate Short and Long-term Safety of the ABSORB Scaffold

CompletedNCT02066623

IHF GmbH - Institut für HerzinfarktforschungCoronary Artery Stenosis

Start: 2013-11-08End: 2021-07-06Updated: 2022-04-01

ABSORB Bioresorbable Scaffold vs. Xience Metallic Stent for Prevention of Restenosis in Patients at High Risk of Restenosis

European Cardiovascular Research CenterCoronary Artery Lesion

Start: 2015-09-28End: 2024-09-30Updated: 2018-08-14

Related Papers

Quality of life of patients with coronary heart disease treated with the bioresorbable vascular scaffold (ABSORB™): 2-year results from the GABI-R-registry.

2022-08-201 citations

No Difference in 30-Day Outcome and Quality of Life in Transradial Versus Transfemoral Access - Results From the German Austrian ABSORB Registry (GABI-R).

2021-11-241 citations

Predictors of scaffold failure and impact of optimized scaffold implantation technique on outcome: Results from the German-Austrian ABSORB RegIstRy.

2021-06-181 citations

Two year efficacy and safety of small versus large ABSORB bioresorbable vascular scaffolds of ≤18 mm device length: A subgroup analysis of the German-Austrian ABSORB RegIstRy (GABI-R)

IJC Heart & Vasculature2020-03-201 citations

Impact of coronary calcification on outcomes after ABSORB scaffold implantation: insights from the GABI-R registry

Coronary Artery Disease2020-03-201 citations

Absorb Bioresorbable Scaffold Versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis: Rationale and Design of the COMPARE ABSORB Trial.

2019-04-167 citations

Everolimus-eluting bioresorbable scaffolds in patients with coronary artery disease: results from the German-Austrian ABSORB RegIstRy (GABI-R).

2017-12-0113 citations